Atlas Trials

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Clinical trial NCT07607587 · RECRUITING

Trial details

NCT number
NCT07607587
Sponsor
Novo Nordisk A/S
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
ObesityOverweight
Start date
2026-05-29
Primary completion
2027-11-19
Enrollment
114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.